Depth of Immunology Portfolio and Pipeline to be Showcased by AbbVie at the 2019 ACR/ARP Annual Meeting
Posted on November 5, 2019
AbbVie, a research-based global biopharmaceutical company, announced it will present data from multiple studies of RINVOQ™ (upadacitinib), HUMIRA® (adalimumab) and SKYRIZI™ (risankizumab) at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting, November 8-13, in Atlanta. A total of 38 abstracts will be presented across multiple rheumatic conditions, including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
“AbbVie looks forward to sharing the latest research across our recently expanded rheumatology portfolio at this year’s meeting, including data that further support our recent FDA approval of RINVOQ,” said Marek Honczarenko, M.D., Ph.D., vice president, global immunology development, AbbVie. “New data being presented on upadacitinib, risankizumab and adalimumab across multiple rheumatic diseases will highlight the potential for all three treatment options to help more patients achieve their treatment goals.”
For the first time, safety and efficacy data evaluating upadacitinib versus placebo for the treatment of signs and symptoms in patients with active AS who had an inadequate response to nonsteroidal anti-inflammatory drugs will be presented during a plenary session at the meeting. A number of upadacitinib RA abstracts will also be featured, including:
- Investigators will present clinical remission data in patients treated with upadacitinib compared to placebo and methotrexate
- Long-term data from the SELECT program will be presented evaluating the efficacy and safety of upadacitinib across clinical measures and patient reported outcomes
- Investigators will share data evaluating upadacitinib compared to adalimumab across clinical and functional responses
- Data will also be presented among patients who experience an initial insufficient response to either upadacitinib or adalimumab and switched to the other therapy
Investigators will also present new patient-reported outcomes in patients with moderate to severe PsA who were treated with adalimumab, as well as data evaluating the safety and efficacy of risankizumab in patients with active PsA.
Subscribe to our FREE newsletter